2025
The prognostic impact of MLH1 promoter hypermethylation in stage I–II endometrial cancer treated with adjuvant radiotherapy: a multi-institutional retrospective study MLH1ph status in stage I-II endometrial cancer
Sherwani Z, Damast S, Fields E, Beriwal S, Horne Z, Kidd E, Leung E, Taunk N, Chino J, Russo A, Dyer M, Albuquerque K, Hathout L. The prognostic impact of MLH1 promoter hypermethylation in stage I–II endometrial cancer treated with adjuvant radiotherapy: a multi-institutional retrospective study MLH1ph status in stage I-II endometrial cancer. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40379143, DOI: 10.1016/j.ijrobp.2025.05.004.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationVaginal brachytherapyEndometrial cancerAssociated with decreased RFSAbsence of lymphovascular space invasionTreated with adjuvant radiation therapyPromoter hypermethylationStage I-II endometrial cancerProportion of locoregional recurrenceStage IMulti-institutional cohort studyAdjuvant radiation therapyLymphovascular space invasionInstitutional review board approvalPatterns of recurrenceKaplan-Meier methodReview board approvalDeficient mismatch repairMismatch repair statusAdjuvant radiotherapyCox proportional hazardsDistant recurrenceLocoregional recurrenceMyometrial invasion
2024
Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis
Hathout L, Sherwani Z, Alegun J, Ohri N, Fields E, Shah S, Beriwal S, Horne Z, Kidd E, Leung E, Song J, Taunk N, Chino J, Huang C, Russo A, Dyer M, Li J, Albuquerque K, Damast S. Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2024, 119: 1158-1165. PMID: 38253292, DOI: 10.1016/j.ijrobp.2024.01.203.Peer-Reviewed Original ResearchRecurrence-free survivalEndometrioid endometrial adenocarcinomaMismatch repair statusAdjuvant radiation therapyOverall survivalRadiation therapyVaginal brachytherapyMismatch repair deficiencyAssociated with worse recurrence-free survivalMulti-institutional retrospective cohort studyTreated with adjuvant radiation therapyAssociated with recurrence-free survivalMultivariate analysisExternal beam radiation therapyRecurrence-free survival ratesMismatch repair deficiency statusBeam radiation therapyGrades 1 to 2Kaplan-Meier methodOutcomes of patientsMulti-institutional analysisRetrospective cohort studyCox proportional hazards modelsProportional hazards modelAdjuvant radiation
2023
Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional Analysis
Sherwani Z, Alegun J, Russo A, Damast S, Albuquerque K, Nwachukwu C, Dyer M, Fields E, Beriwal S, Horne Z, Vergalasova I, Ohri N, Taunk N, Chino J, Kidd E, Leung E, Song J, Hathout L. Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s8. DOI: 10.1016/j.ijrobp.2023.06.217.Peer-Reviewed Original ResearchEndometrioid endometrial cancerEarly-stage endometrioid endometrial cancerExternal beam radiation therapyAdjuvant radiation therapyLymphovascular space invasionOverall survivalGrade 3Radiation therapyStage IMultivariate analysisWorse RFSWorse OSEndometrial cancerUnivariate analysisMulti-institutional retrospective cohort studyFIGO 2009 stage IRecurrence-free survival ratesCox proportional hazards modelPost-surgical stagingRetrospective cohort studyKaplan-Meier methodDeep myometrial invasionFIGO grade 1Proportional hazards modelBeam radiation therapyManagement of Pathologic Node-Positive Prostate Cancer following Radical Prostatectomy
Hayden C, Rahman S, Lokeshwar S, Choksi A, Kim I. Management of Pathologic Node-Positive Prostate Cancer following Radical Prostatectomy. Current Oncology Reports 2023, 25: 729-734. PMID: 37071296, DOI: 10.1007/s11912-023-01420-6.Peer-Reviewed Original ResearchConceptsAdjuvant androgen deprivation therapyNode-positive prostate cancerStandard of careRadical prostatectomyRadiation therapyProstate cancerPathologic node-positive patientsAdjuvant radiation therapyAndrogen deprivation therapyNode-positive patientsSalvage radiation therapySubset of patientsRobust clinical trialsProstate cancer patientsRecent systematic reviewDeprivation therapyCause mortalityTreatment optionsCancer patientsClinical trialsPatientsControl groupSystematic reviewTherapyProstatectomyFactors associated with the use of adjuvant radiation therapy in stage III melanoma
King A, Lee V, Yu B, Mirza F, Zogg C, Yang D, Tran T, Leventhal J, An Y. Factors associated with the use of adjuvant radiation therapy in stage III melanoma. Frontiers In Oncology 2023, 13: 1005930. PMID: 36816935, PMCID: PMC9929351, DOI: 10.3389/fonc.2023.1005930.Peer-Reviewed Original ResearchAdjuvant radiation therapyStage III melanomaNational Cancer Data BaseRadiation therapyPositive nodesNational Comprehensive Cancer Network guidelinesUse of RTUtilization of RTMultivariable logistic regression analysisPalliative intent therapyDistant metastatic diseasePrimary treatment modalityMajority of patientsMicroscopic residual tumorHospital-specific factorsMultivariable regression analysisLogistic regression analysisRegression analysisMetastatic diseaseOverall cohortResidual tumorDisease benefitNetwork guidelinesPalliative careMean age
2022
Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).
Gross N, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Wargo J, Weber R, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal Of Clinical Oncology 2022, 40: 9519-9519. DOI: 10.1200/jco.2022.40.16_suppl.9519.Peer-Reviewed Original ResearchPathologic complete responseOverall response rateCutaneous squamous cell carcinomaPhase II trialPathologic responseLong-term outcomesNeoadjuvant immunotherapySquamous cell carcinomaAdverse eventsCSCC-HNII trialCell carcinomaGrade 2 adverse eventsPilot phase II trialGrade 3 diarrheaMajor pathologic responsePathologic partial responseAdjuvant radiation therapyWarrants further investigationMedian followRECIST v1.1Adjuvant radiationPrimary endpointRecurrent diseaseSecondary endpointsThe Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas
Hong CS, Omay SB. The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas. Current Oncology 2022, 29: 1408-1421. PMID: 35323318, PMCID: PMC8947636, DOI: 10.3390/curroncol29030118.Peer-Reviewed Original ResearchConceptsSurgical approachBenign primary brain tumorsAggressive surgical resectionAdjuvant radiation therapyOptimal surgical approachInvasive surgical approachPrimary brain tumorsSurgical treatment paradigmMulti-modal managementEloquent neural structuresEndoscopic endonasal approachBenign biologyClinical sequelaeHypothalamic dysfunctionOpen resectionSurgical resectionSignificant morbidityOptic apparatusSafe resectionTumor recurrenceTranscranial surgeryTreatment paradigmDisease entityHypothalamic functionLateral approach
2021
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchA Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer
Bellon JR, Chen YH, Rees R, Taghian AG, Wong JS, Punglia RS, Shiloh RY, Warren LEG, Krishnan MS, Phillips J, Pretz J, Jimenez R, Macausland S, Pashtan I, Andrews C, Isakoff SJ, Winer EP, Tolaney SM. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 45-52. PMID: 33713742, DOI: 10.1016/j.ijrobp.2021.03.002.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast-Conserving TherapyDose-limiting toxicityBCT cohortRadiation therapyConcurrent cisplatinMastectomy cohortBreast cancerEarly-stage triple-negative breast cancerThree-year disease-free survivalPhase 1 dose-escalation trialStage IILocal-regional recurrence ratePhase 2 doseAdjuvant radiation therapyDisease-free survivalDose-escalation trialPhase 1b trialDose of cisplatinHER2-positive tumorsEligible patientsUrinary infectionAdditional patientsDose escalationRecurrence rateA Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaOverall survivalEndometrial carcinomaRadiation therapyAdjuvant chemotherapyAdjuvant therapyPALN recurrenceSystemic chemotherapyRFS ratesMulti-institutional retrospective cohort studyStage IIIC endometrial cancerRecurrence-free survival ratesLymph node recurrenceSequential radiation therapyAdjuvant radiation therapyRetrospective cohort studyGrade 3 tumorsAdjuvant treatment regimensKaplan-Meier methodVaginal cuff brachytherapyHigh rateSequence of treatmentChemotherapy concurrentNodal radiationNode recurrence
2020
Dermatologic toxicities associated with radiation therapy in women with breast cancer
Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.Peer-Reviewed Original ResearchBreast cancerRadiation therapyDermatologic toxicitiesEarly-stage breast cancerRadiation-induced morpheaAdjuvant radiation therapyBreast-conserving surgeryStage breast cancerStandard of careRadiation-induced fibrosisRadiation recallCutaneous toxicityRadiation dermatitisCutaneous sequelaeClinical presentationCutaneous malignanciesPatients' qualityTherapyCancerWomenToxicityMorpheaSequelaePatientsSurgery
2019
Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head & Neck 2019, 41: 3551-3563. PMID: 31294897, PMCID: PMC6742559, DOI: 10.1002/hed.25873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellCombined Modality TherapyDatabases, FactualDisease-Free SurvivalEndoscopyFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedOtorhinolaryngologic Surgical ProceduresParanasal Sinus NeoplasmsPropensity ScoreRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTime FactorsConceptsSquamous cell carcinomaRadiation therapyEndoscopic surgeryPropensity score-matched analysisAdjuvant radiation therapyNational Cancer DatabasePostoperative radiation therapyKaplan-Meier methodTiming of surgeryDay of surgeryShorter postoperative timeMultivariable linear regressionOverall survivalPostoperative timeSinonasal malignanciesCell carcinomaSurgical approachNeck cancerCancer DatabaseParanasal sinusesSurvival advantageNasal cavitySurgeryPatientsExtended OSEvaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma
Cheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatology 2019, 155: 803-811. PMID: 30825411, PMCID: PMC6583886, DOI: 10.1001/jamadermatol.2019.0267.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMerkel cell carcinomaPositive lymph nodesDisease-specific survivalLymph nodesSEER registryEligible casesPatient survivalPatient counselingCell carcinomaPrognostic indicatorPopulation-based US cohortLong-term patient survivalAJCC N stagingCancer-accredited facilitiesAdjuvant radiation therapyRetrospective cohort studyAdjuvant chemoradiation therapyEnd Results registryTreatment planningHigh mortality rateSEER data setLNR statusTraditional TNMAdjuvant therapy
2018
Epithelial–Myoepithelial Carcinoma Presenting as a Pseudo Veno-Lymphatic Malformation
Li E, Distefano A, Sinard J, Wong A, Pointdujour-Lim R. Epithelial–Myoepithelial Carcinoma Presenting as a Pseudo Veno-Lymphatic Malformation. Ophthalmic Plastic And Reconstructive Surgery 2018, 34: e157-e160. PMID: 30080758, DOI: 10.1097/iop.0000000000001179.Peer-Reviewed Original ResearchConceptsVeno-lymphatic malformationEpithelial-myoepithelial carcinomaRight eye painAdjuvant radiation therapyComplete surgical excisionFluid-fluid levelsIntralesional cystsEye painCarcinoma presentingSurgical excisionFinal diagnosisHistopathologic evaluationRadiologic workupRare neoplasmCystic spacesRadiation therapySalivary glandsPainCarcinomaMalformationsPresentingNeoplasmsHistopathologyTherapyWorkupHeterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy.
Ghabili K, Nguyen K, Lu A, Hsiang W, Shuch B, Leapman M. Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 144-144. DOI: 10.1200/jco.2018.36.6_suppl.144.Peer-Reviewed Original ResearchIR prostate cancerAdjuvant radiation therapyNational Cancer DatabaseEarly oncologic outcomesClinical stageAdverse pathologyProstate cancerRadical prostatectomyRadiation therapyActive surveillanceIR patientsOncologic outcomesPathologic outcomesGS 3Intermediate-risk prostate cancerNational cancer registry dataIntermediate-risk featuresGS 4Cancer registry dataIR definitionLogistic regression analysisGleason upgradeLR patientsEarly outcomesIR groupNational trends in the management of patients with positive surgical margins at the time of radical prostatectomy.
Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.Peer-Reviewed Original ResearchAdjuvant radiation therapyAndrogen deprivation therapyPositive surgical marginsNational Cancer DatabaseAdjuvant therapyRadical prostatectomyRadiation therapyProstate cancerPathologic featuresSurgical marginsAddition of ADTAdjuvant androgen deprivation therapyStudy periodPre-treatment PSAPrimary definitive treatmentMajority of patientsManagement of patientsGleason grade groupCourse of managementOptimal management approachNon-academic facilitiesLogistic regression modelsBinary logistic regression modelAnalysis menDeprivation therapyA gene expression signature predicts recurrence-free survival in meningioma
Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget 2018, 9: 16087-16098. PMID: 29662628, PMCID: PMC5882319, DOI: 10.18632/oncotarget.24498.Peer-Reviewed Original ResearchAdjuvant radiation therapyRadiation therapy
2017
Adjuvant Radiation Therapy Improves Overall Survival After Margin-Positive Resection of Thymic Carcinoma
Johnson S, Kole A, Bledsoe T, Park H, Decker R. Adjuvant Radiation Therapy Improves Overall Survival After Margin-Positive Resection of Thymic Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s211-s212. DOI: 10.1016/j.ijrobp.2017.06.523.Peer-Reviewed Original ResearchAdjuvant radiation therapyMargin-positive resectionThymic carcinomaOverall survivalRadiation therapyResectionCarcinomaTherapyRadiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings
Hong JC, Rahimy E, Gross CP, Shafman T, Hu X, Yu JB, Ross R, Finkelstein SE, Dosoretz A, Park HS, Soulos PR, Evans SB. Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings. Practical Radiation Oncology 2017, 8: e79-e86. PMID: 28888675, DOI: 10.1016/j.prro.2017.07.005.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyMedian MHDCardiac riskRadiation therapyBreast cancerCardiac toxicityRisk of RTCommunity settingsLeft-sided breast cancerThree-dimensional conformal radiation therapyDeep inspiration breath holdCardiovascular risk factorsIschemic heart diseaseInspiration breath holdBreast cancer treatmentMultivariable linear regressionConformal radiation therapyCommunity practiceCardiac doseCardiac eventsBreast conservationMultivariable analysisMean heartContemporary community practiceExcess riskRisk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply